NRAS and acute myeloid leukemia: Further, RUNX1-mutated CD34 + primary AML blasts cocultured with HUVEC-AD52 were more sensitive to BTX-A51 than NRAS and IDH2 mutated CD34 + primary AML blasts (IC50 19 nM vs. 38nM, p < 0.01, Fig. 5B–C).